

ASX ANNOUNCEMENT MARKET RELEASE

28 November 2024

2024 CHAIRMAN AND CEO ANNUAL GENERAL MEETING ADDRESSES AND PRESENTATION

Artrya Limited (ASX:AYA), ('Artrya' or the 'Company'), a medical technology company focused on commercialising its patented artificial intelligence platform that detects key coronary artery disease imaging markers, advises the Chairman, CEO's address and Presentation to the Annual General Meeting of Shareholders to be held at 10:00 am AWST today are attached to this announcement.

This announcement was approved by the Board.

For further information please contact:

Investor Enquiries:

Danny Younis
+61 420 293 042
danny.younis@automicgroup.com.au

Media Relations:

Rama Razy
+61 498 44 142
rama.razy@automicgroup.com.au

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at-risk patients. The company has developed deep learning algorithms that predict and prevent acute coronary events.

For more information, see www.artrya.com

Chairman's Address to the Annual General Meeting of Shareholders

Welcome to everyone attending our 2024 Annual General Meeting whether that be in person or virtually. It has been another tough year for Artrya but I can say with confidence that we have laid solid foundations for the growth ahead. Mat Regan, as the Company's CEO, had much work to do when he joined in April last year. His main priorities were:

- to get things back on track with the FDA including employing US based competent and experienced experts with a proven track record in dealing with the FDA; and
- increase the capability of the product development team and commercialise the software.

In relation to the first priority, a Q-Sub meeting was held with the FDA in June 2023 where the roadmap of work to be undertaken by Artrya was agreed. The right people to undertake this work were employed and changes were made at senior levels within the Company as well as with the product development team.

At last year's Annual General Meeting, Dr Girish Dwivedi and Abdul Ihdahid demonstrated the software which was close to having a product for commercial use. I am pleased to say that with further development, we have a commercial product that clinicians can use, subject to having the necessary regulatory approvals.

We intend to do a presentation shortly of the current version of the software as a clinician would use it. In parallel with the further development of the product to FDA application status, Artrya has also concluded pre-FDA agreements with Northeast Georgia Health System, Tanner Health and Cone Health in the US. The purpose behind these agreements is to generate income from these health systems as soon as possible post FDA clearance. In total, these health systems conduct approximately 15,000-20,000 Coronary Computed Tomography Angiography (CCTA) scans per year.

We are in advanced discussions with much larger US health systems and we will continue to work with them to execute contracts during CY25.

One of the key benefits of the Artrya software is the real time, point of care approach. Clinicians can treat the patient shortly after the CCTA scan is taken, retaining control over the reporting and their patient. This is becoming important as US hospital systems increasingly adopt a value-based care approach to patient care. Our competitors do not offer a cloud-based point of care solution, which is a key differentiator for Artrya and a clear market advantage. John and Mat will cover this in more detail in their presentation and product demonstration shortly.

Closer to home, we are generating small revenue from our first commercial client in Australia, The Cardiac Centre of NSW based in Wollongong.

We are dealing with much larger Australia wide radiology groups and are confident of entering into commercial arrangements with them in the coming months.

Having said that, I want to be clear that our primary focus is very much on the US market where substantial reimbursement codes already exist for the use of AI-assisted CCTA scan interpretation for coronary artery disease detection.

The US is a large market where approximately 4.4 million¹ CCTA scans are conducted every year and growing at over 6% per annum. This growth will be further fuelled by a recent decision by the Centers for Medicare and Medicaid Services (CMS) to more than double the Medicare reimbursement rates for CCTA scans, raising

¹ Frost & Sullivan Analysis – Artrya Prospectus - refer ASX release 24 November 2021

payments from US\$175 to US\$357². Upon FDA clearance of our current 510(k) application, Artrya will be well positioned to access this reimbursement.

The payment rate for Automated Plaque Analysis remains at US\$950² per scan, while Fractional Flow Reserve reimbursement has increased from US\$997 to US\$1,017². Artrya is targeting FDA approvals for Salix Coronary Plaque (SCP) and Salix Coronary Flow (SCF) by the end of CY25 giving us access to a combined reimbursement of approximately US\$2,000 for both procedures.

The American College of Cardiology (ACC) and the Society of Cardiovascular Computed Tomography (SCCT) are recommending CCTA as the first line test for patients with chest pain, rather than other traditional modalities.

The tailwinds for Artrya are clear and favourable.

The staff are all aligned and incentivised around achieving FDA approval for the SCA, SCP and SCF products during CY25.

It goes without saying that a growth company such as Artrya cannot deliver on the opportunities available if the Company isn't well funded. To that end, we completed a successful \$5m raising earlier this month. The Board decided that we needed to extend the runway before running cash too low and reduce the risks associated with the state of capital markets. Dilution was minimised and we brought on a number of new institutional shareholders, as well as Healthliant Ventures, the venture arm of US hospital system Tanner Health, enhancing and widening our investor support base.

In closing, I would like to thank our long-standing shareholders for your patience and offer a big welcome to our new shareholders who have joined us for what we consider to be an exciting journey ahead. I would also like to pay a big thank you to my fellow Board members in Kate and Jacque, to Mat and JK and the whole Artrya team who have worked tirelessly over the last 12 months to get us to this point and provide a great springboard for the year ahead.

Thank you

Bernie Ridgeway
Chairman
28 November 2024

² <https://cardiovascularbusiness.com/topics/cardiac-imaging/cms-increases-medicare-payments-cardiac-ct-ccta>

CEO's Address to the Annual General Meeting of Shareholders

Good morning, and thank you, Bernie, and thank you all for joining us for our Annual General Meeting. My name is Mat Regan, and I am the CEO of Artrya.

As Bernie mentioned, my primary focus over the past year has been to refine our Salix product to meet the high-performance standards expected of a commercial solution.

On Slide 3, I have listed the key achievements in the last 12 months.

A key priority has been re-engaging with the FDA to prepare for entry into the U.S. market, all while carefully managing our financial runway. Our goal is to secure FDA clearance for Salix Coronary Anatomy, which we anticipate in the first quarter of CY25.

We took a cautious yet strategic approach by scheduling a second Q-Sub meeting with the FDA in August this year to ensure we were on track. We submitted our 510(k) application at the end of September this year with a high level of confidence.

On the commercial front, we secured strategic partnerships with three U.S. hospital groups. These partnerships serve three critical purposes:

1. Testing our software into hospital imaging workflow systems,
2. Further validating our software by clinicians, and
3. Streamlining the sales cycle to generate revenue as soon as possible after SCA achieves FDA clearance.

Closer to home, we successfully launched Salix in Australia and have begun generating revenue. The feedback from clinicians has been positive, particularly regarding the benefits of our plaque assessment and unique point-of-care approach. Our collaboration with The Cardiac Center NSW has increased awareness and interest, and we are in active discussions with top-tier imaging groups across Australia.

The rigorous process of preparing our 510(k) submission has also strengthened our ability to navigate future applications with greater assurance.

Looking at our Product Roadmap on Slide 4, across the bottom of the slide is Salix Coronary Anatomy which is the subject of our current FDA application. Our intention is to file the 510(k) application for Salix Coronary Plaque (SCP) (left hand side of the slide) in the first half of CY25 followed by Salix Coronary Flow (SCF) mid next year. The goal is to have both SCP and SCF approved by the end of CY25.

Slide 5 sets out the current CCTA reporting state and the approach that our main US competitors take. The current system, which is the top line, is very manual, time consuming and generally does not report the high-risk plaque because it is very time consuming and difficult to see with the human eye.

The middle line depicts our main competitors being HeartFlow, Cleerly and Elucid. The CCTA scans get sent off-site to their premises where there is manual work up of the images, a fixed report is generated and sent back to the clinician. This process is time consuming, expensive, and the clinician cannot amend the report if he disagrees with the findings and has to request an additional report at extra cost.

The bottom line shows the Salix process which is fully cloud based with no human in the loop. It is the only Point of Care approach which takes approximately 10 minutes to generate the report for the clinician. The clinician can review, amend where necessary and approve the report and provide a treatment regime for the patient in the same visit.

Slide 6 sets out why we are focused on the US market.

There are 4.4 million scans per annum and growing at a rate of better than 6% year on year. The Centres of Medicare and Medicaid (CMS) has recently increased the re-imbursements for CCTA to encourage clinicians to use this pathway and we expect further CCTA growth because of this.

Slide 7 drills down to show how Artrya fits into the re-imbursement regime.

Post FDA clearance, Artrya will charge a monthly subscription for the use of SCA. When SCP is approved, we can charge a fee per scan where the re-imbursement is established at US\$950 per scan. Approximately 70% of patients who have a scan will require a plaque analysis. About 50% of those patients who have a plaque assessment will have a potentially obstructive lesion and will be sent for a non-invasive blood flow assessment. Once SCF is cleared by the FDA, Artrya can access the re-imbursement of US\$1,017 per scan.

On Slide 8, there are significant tailwinds and drivers of growth in the US market. The American College of Cardiology and the American Heart Association are recommending CCTA as the first line evaluation for patients with chest pain.

As mentioned earlier, attractive re-imbursement exists for AI enabled CCTA. This is a tremendous advantage as many healthcare businesses trying to penetrate the US market spend years getting access to re-imbursement codes. Additionally, there are now newly published studies and pathways for the treatment of patients that have non-calcified and high-risk plaque.

I would now like to invite John to conduct a demonstration of the software.

On slide 10, our priorities for CY25 are clear:

1. We are focused on the US market given the attractive reimbursement landscape.
2. To access that market, we will continue to engage with the FDA to approve SCA, SCP and SCF
3. Secure U.S. revenue as soon as the respective approvals are granted, and
4. Expand our client base in Australia to further validate Salix and grow our US pipeline with strategic hospital groups to drive growth.

In closing, I want to extend my heartfelt thanks to our team for their dedication and hard work, to our partners for their invaluable support, and to you, our shareholders, for your continued trust.

As we look to the future, we are more energized than ever to drive progress and deliver on our mission. Thank you for your support, and I look forward to the journey ahead.

Mathew Regan
Chief Executive Officer
28 November 2024

ARTRYA

Coronary Heart Disease We See You

2024 AGM ARTRYA Presentation



Important notice and disclaimer

IMPORTANT NOTICE

By continuing to read, use or act on this presentation, you acknowledge that you have read, and you agree to be bound by, the following terms and conditions. If you do not agree to be so bound, you should immediately return this presentation to Artrya Limited (Company).

This presentation has been prepared by the Company to provide summary information about the Company and its associated entities which carry on the business of using artificial intelligence (AI) software to more accurately detect coronary artery disease (CAD) as at the date of this presentation. It has been prepared by the Company with due care but no representation or warranty, express or implied, is provided in relation to the accuracy or completeness of the information. The information in this presentation remains subject to change without notice. The Company has no obligation to update or correct this presentation.

NOT A DISCLOSURE DOCUMENT

The Company has prepared this presentation in anticipation of its proposed initial public offering (IPO) of ordinary shares (Shares) in the Company (Offer). This presentation is provided for general information purposes only.

This presentation is not a prospectus, product disclosure statement, pathfinder document or any other form of disclosure document or other offering document under the Corporations Act 2001 (Cth) (Corporations Act) and does not contain all the information which would be required to be disclosed in a prospectus or other disclosure document. The information presented in this presentation may differ materially from that presented in any disclosure document prepared in connection with any offer of securities. It does not constitute an offer to sell, or a solicitation of an offer to buy, Shares in any jurisdiction and neither this document nor any of the information contained herein shall form the basis of any contract or commitment.

The information contained in this presentation is for information purposes only. It is intended only for Recipients (as defined below) to whom it is delivered personally by or on behalf of the Company. The information contained in this presentation is of general background and does not purport to be complete. The information contained in this presentation does not constitute investment or financial product advice (nor taxation or legal advice) and is not intended to be used as the basis for making an investment decision. In providing this presentation, the Company has not considered the objectives, financial position or needs of any particular Recipients.

This presentation and the information contained within this presentation is strictly confidential and is intended for the exclusive benefit of the Recipient to which it is presented. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of the Company. By accepting the invitation and attending this presentation you agree to keep this presentation private and confidential, not to disclose any of the information contained in this presentation to any other person and not to copy, use, publish, record, disclose, disseminate or reproduce the information in this presentation to any party, in whole or in part, without the prior written consent of the Company, which may be withheld in its absolute discretion. Distribution of this presentation may be restricted or prohibited by law. Any failure to comply with such restrictions may constitute a violation of applicable securities law.

ELIGIBLE RECIPIENTS

This presentation is being provided to you (Recipient) on the basis that you are, and you represent and warrant that:

- if you are in Australia, you are the holder (or representative of a holder) of an Australian financial services licence and are also a "professional investor" or "sophisticated investor" (as those terms are used in section 708(11) and section 708(8) respectively of the Corporations Act and are also, in each case, a "wholesale client" (as defined in section 761A of the Corporations Act); or
- if you are outside Australia, you are a person to whom the provision of the information in this presentation is permitted by laws of the jurisdiction in which you are situated without the need for registration, lodgement or approval of a formal disclosure document or any other filing or formality in accordance with the laws of that foreign jurisdiction; and
- you are not in the United States and are not acting for the benefit or account of a person in the United States; and
- wherever you are located, you are a person who is permitted under applicable law and regulation to receive and view information of the kind contained in this presentations.

If you are not such a person, you are not entitled to read or attend this presentation and must notify the Company immediately and promptly return this presentation to the Company and destroy all copies, whether held in electronic or printed form or otherwise, without retaining any copies. In accepting this presentation, you warrant that you are an investor within the scope of the above paragraphs and that you accept this presentation on the basis set out in this notice.

NO LIABILITY

While care has been taken in preparing the information in this presentation, no representation or warranty, express or implied, is made as to the currency, accuracy, reliability, completeness or fairness of the information, opinions and conclusions contained in this presentation. None of the Company, its related bodies corporate (as defined in the Corporations Act), shareholders or affiliates, nor any of their respective officers, directors, employees, affiliates, partners, representatives, consultants, agents or advisers (including, without limitation, none of the advisers nor their related bodies corporate (as defined in the Corporations Act), shareholders or affiliates, nor any of their respective officers, directors, employees, affiliates, partners, representatives, consultants, agents or advisers, together the "Advisers") (each a "Limited Party") guarantees or makes any representations or warranties, express or implied, as to or takes responsibility for, the currency, accuracy, reliability, completeness or fairness of this presentation nor the information, opinions and conclusions contained in this presentation. The Company does not represent or warrant that this presentation is complete or that it contains all material information about the Company. To the maximum extent permitted by law, each Limited Party expressly disclaims any and all liability (whether direct, indirect, consequential or contingent), including, without limitation, any liability arising out of fault or negligence on the part of any person, for any expenses, damages, costs or loss arising from the use of information contained in this presentation including representations or warranties or in

relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom. The Company has not carried out due diligence investigations in connection with the preparation of this presentation, nor has it verified any of the contents of this presentation. You must consider your own financial situation, objectives and needs and conduct your own independent investigations, assessments and enquiries, including obtaining investment, legal, tax, accounting and other such advice as you consider necessary or appropriate. This presentation should not be relied on by the recipient in considering the merits of any particular transaction.

None of the Advisers have authorised, permitted or caused the issue or lodgement, submission, dispatch or provision of this presentation and there is no statement in this presentation which is based on any statement made by any of the Advisers. To the maximum extent permitted by law, each of the Advisers expressly disclaims all liabilities in respect of, and make no representations regarding, and take no responsibility for, any part of this presentation.

None of the Company nor any of the other Limited Parties act or are responsible as a fiduciary to you, your directors, officers, employees, affiliates, partners, representatives, consultants, agents, advisers, security holders, creditors or any other person. You and each of the Company and the other Limited Parties expressly disclaim any fiduciary relationship. The Company and the other Limited Parties are relying on you complying with this important notice and disclaimer and on the truth and accuracy of the representations, warranties, undertakings and acknowledgments given by you.

FUTURE PERFORMANCE & FORWARD-LOOKING STATEMENTS

This presentation may contain certain forward looking statements, forecasts, estimates, projections and comments about future events, including the Company's expectations about the performance of its businesses and certain strategic transactions. Forward looking statements can generally be identified by the use of forward looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "goals", "aims", "target" and other similar expressions within the meaning of securities laws of applicable jurisdictions. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward looking statements. Forward looking statements involve inherent risks and uncertainties, both general and specific, and there is a risk that such predictions, forecasts, projections and other forward looking statements will not be achieved. A number of important factors could cause the Company's actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward looking statements, and many of these factors are beyond the Company's control. Any forward looking statements are provided as a general guide only, and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainty and other factors, many of which are outside the control of the Company. As such, undue reliance should not be placed on any forward looking statement. Past performance is not necessarily a guide to future performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of any forward looking statements, forecast financial information or other forecast. Nothing contained in this presentation nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of the Company. None of the Company, or any other Limited Party, makes any representation or warranty as to the accuracy of any forward looking statements contained in this presentation. Forward looking statements speak only as at the date of this presentation and the Limited Parties disclaim any obligations or undertakings to release any update of, or revisions to, any forward looking statements in this presentation.

NO RELIANCE ON PRESENTATION

A Recipient of this presentation must make their own assessment of the matters contained herein and rely on their own investigations and judgment in making an investment in the Company.

THIS IS NOT AN OFFER OR FINANCIAL PRODUCT ADVICE

This presentation is not, and does not constitute, an offer to sell, or the solicitation of an offer to buy, invitation or recommendation to purchase any securities or other investment products in the United States or in any other jurisdiction and neither this presentation, nor any of the information contained herein, shall form the basis of any contract or commitment. Securities of the Company have not been, and will not be, registered under the U.S. Securities Act or the securities laws of any state or other jurisdiction of the United States. Accordingly, any such securities may not be offered or sold, directly or indirectly, in the United States unless they have been registered under the U.S. Securities Act (which the Company has no obligation to do or procure) or are offered and sold pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and any other applicable state securities laws.

The distribution or release of this presentation outside Australia may be restricted by law and you should observe any such restrictions.

FINANCIAL AND OTHER DATA

A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation. All dollar values are in Australian dollars (A\$), unless otherwise stated.

PAST PERFORMANCE

Historical financial information and pro-forma financial information is given for illustrative purposes only and should not be relied upon as (and is not) an indication of the Company's views on its future financial performance or condition. Past performance of the Company cannot be relied upon as an indicator of (and provides no guidance as to) future Company performance.

ACKNOWLEDGMENTS

In accessing, receiving or reviewing this presentation, each Recipient acknowledges and agrees to the foregoing terms and conditions. Any failure to comply with such terms and conditions may constitute a violation of applicable securities laws.

FY24 Achievements

Considerable momentum towards commercialising Salix, primarily in Australia and the US

- ✓ Completed second Q-Sub with the FDA (Aug 24) for Salix Coronary Anatomy
- ✓ 510(k) FDA application submitted (Sept 24) for Salix Coronary Anatomy
- ✓ Received FDA registration for medical device data system, Salix Ingest, a key component of Salix Coronary Anatomy
- ✓ Commercial launch in Australia with The Cardiac Centre NSW
- ✓ Strategic Partnerships with three hospital groups in the US, providing access to 15 hospitals and hundreds of specialist clinics along the US East Coast
- ✓ Granted first patent in the UK
- ✓ Secured agreement for Salix AI to analyse world's largest database of CCTA images, funded by \$3.3 million under the Medical Research Future Fund
- ✓ Contributed three articles to peer-reviewed journals building Artrya's credibility in the global clinical community


Salix[®] Product Roadmap

Artrya's product pipeline goes further & moves us towards predicting the patient at risk.



Current State/Competition

Salix® is system agnostic and simple to deploy, use, and update



Heart disease is a large and growing health challenge, particularly in the US

US\$4.18 billion*

Total Addressable Market (US)

U.S. patients undergoing CCTA + Plaque Assessment

Targeted Approach in US

Greenfield


- Focus on large/medium regions and multi-facility health systems.
- Groups with simple pre-authorization and value-based care focus.

Replace Existing Market Share

- Target dissatisfied customers looking for point-of-care, cost-effective CCTA solutions.

Limited Focus

- Small, regional markets and physician practices.



* Assumptions

- National Average Medicare Rate
 - Reimbursement for Automated Plaque – US\$950 (CPT 0625T³)
 - Reimbursement for FFRCT – US\$1,017 (CPT 75580³)
- TAM estimated as total of all scans receiving Plaque reimbursement only
- FFRCT procedures have not been included in TAM

6 ¹ <https://www.dicardiology.com/article/rising-demand-cardiac-ct-positions-market-major-growth>
² Frost & Sullivan Analysis – Artrya Prospectus – <https://wcsecure.weblink.com.au/pdf/AYA/02456983.pdf>
³ <https://clearlyhealth.com/hubfs/downloads/clearly-analysis-billing-code-guide.pdf>

Salix® SaaS Pricing Model – US example

Hybrid monthly subscription and fee-per-analysis pricing model

Salix Coronary Anatomy

Plaque visualisation, CCTA reporting

SCA

Salix Coronary Plaque

Detailed Plaque and Dispersion

SCP

Salix Coronary Flow*

Non-invasive Blood Flow Assessment

SCF

Monthly Subscription

All CCTA scans attract this monthly fee

Fee-per-Analysis

70%² of scans attract this fee
US\$950¹ (CPT 0625T)

Fee-per-Analysis

50% of SCP attract this fee
US\$1,017¹ (CPT 75580)

- Benefits:**
- Provides a single CCTA reporting platform, saving costs
 - Flexibility on which patients should receive plaque or FFR assessment
 - Enhances clinician efficiency and productivity

¹ <https://cardiovascularbusiness.com/topics/cardiac-imaging/cms-increases-medicare-payments-cardiac-ct-ccta>

² <https://pubmed.ncbi.nlm.nih.gov/34127407/>

Drivers of Growth in US Market

Industry tailwinds fuel the high growth outlook, rapidly accelerating growth of CCTA and plaque assessment

Associations and Reimbursement

- ACC and AHA recommend CCTA as a first-line evaluation for patients with chest pain, in their guidelines¹
- CCTA reimbursement has doubled to US\$357 per scan²
- FFR-CT reimbursement increased to US\$1,017²
- AI Plaque analysis now classified as a category 1 code under CMS with reimbursement of \$950²



Plaque Assessment and Treatment

- **SCOT-HEART trial** - Further results show CCTA management led to a lasting 10-year reduction in deaths and heart attacks.³
- **Plaque Staging** - A new plaque-burden staging system helps clinicians tailor treatments based on plaque volume.⁴
- **CONFIRM2 Study** - Best predictors of major heart risks are non-calcified plaque volume and % diameter stenosis only.⁵
- **PREVENT Study** - Preventive coronary intervention lowered major heart risks in patients with high-risk plaques better than medical therapy alone.⁶

1 <https://doi.org/10.1161/CIR.0000000000001029>

2 <https://cardiovascularbusiness.com/topics/cardiac-imaging/cms-increases-medicare-payments-cardiac-ct-ccta>

3 <https://www.auntminnieeurope.com/clinical-news/ct/article/15682946/researchers-unveil-10year-results-of-scottish-ct-trial#:~:text=After%2010%20years%20of%20follow,%3D%2090%2C%204.3%25%20vs.>

4 Coronary CTA plaque volume severity stages according to invasive coronary angiography and FFR - Journal of Cardiovascular Computed Tomography

5 <https://www.tctmd.com/news/confirm2-shows-power-ai-qct-use-plaque-features-predict-cad-events>

6 <https://www.acc.org/Latest-in-Cardiology/Articles/2024/04/02/17/02/mon-11am-preventive-pci-acc-2024#:~:text=PCI%20performed%20preventively%20in%20patients,Late%2DBreaking%20Clinical%20Trial%20session>

Salix® Demonstration



Outlook - six key priorities for CY25

Complete regulatory approvals and enter US market

- 1 Salix Coronary Anatomy:** clearance expected **first half of CY25**
- 2 Salix Coronary Plaque:** clearance targeted for end of **mid 2025**
- 3 Salix Coronary Flow:** clearance targeted for end of **CY25**
- 4 First USA Revenues:** **second half of CY25**
- 5 US market:** continue to expand client base and conclude agreements with large health systems
- 6 Australian Clients:** continue to validate and commercialise our product with **new Australian clients**

Thank You

